Summary
Death associated with hepatic decompensation and fatty liver developing during tetracycline administration is reported in an adult man without predisposing hormonal abnormality. Attention is focused on the dose-related hepatotoxicity of the tetracyclines, and caution in the intravenous administration of this antibiotic, even in the male, is stressed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schultz JC, Adamson JS Jr, Workman WW, et al: Fatal liver disease after intravenous administration of tetracycline in high dosage. New Engl J Med 269:999–1004, 1963
Kunelis CT, Peters RL, Edmondson HA: Fatty liver of pregnancy and its relationship to tetracycline therapy. Amer J Med 38:359–377, 1965
Peters RL, Edmondson HA, Mikkelsen WP, et al: Tetracycline-induced fatty liver in non pregnant patients. A report of six cases Amer J Surg 113:622–632, 1967
Schiffer MA: Fatty liver associated with administration of tetracycline in pregnant and non pregnant women. Amer J Obset Gynec 96:326–332, 1966
Winterling AN, Goldman RL: Hepatic and renal lesions in a case of tetracycline toxicity during long term estrogen therapy after orchiectomy. Calif Med 102:314–320, 1965
Dowling HF, Lepper MH: Hepatic reactions to tetracycline. JAMA 188:307–309, 1964
Lepper MH, Wolfe CK, Zimmerman HJ, et al: Effect of large doses of aureomycin on human liver. Arch Intern Med 88:271–283, 1951
Lepper MH, Zimmerman H, Carroll G, et al: Effect of large doses of aureomycin, terramycin, and chloramphenicol on livers of mice and dogs. Arch Intern Med 88:284–295, 1957
Miller SEP, MacSween RMM, Glen ACA, et al: Experimental studies on the hepatic effects of tetracycline. Brit J Exp Path 48:51–57, 1967
Steiner G, Bradford W, Craig JM: Tetracycline induced abortion in the rat. Lab Invest 14:1456–1463, 1965
Seto JT, Lepper MH: The effect of chlortetracycline, oxytetracycline and tetracycline administered intravenously on hepatic fat content: a quantitative method of study including failure of some vitamins and other drugs to mitigate the effect. Antibiot Chemother 4:666–672, 1954
Lewis M, Schenker S, Combes B: Studies on the pathogenesis of tetracycline induced fatty liver. Amer J Dig Dis 12:429–438, 1967
Andre T: Studies on distribution of tritium-labeled dihydrostreptomycin and tetracycline in body. Acta Radiol 142:Suppl:1–89, 1956
Zuckerman AJ, Baker SF, Dunkley LJ: The effect of tetracycline on human liver cells in culture. Brit J Exp Path 49:20–23, 1968
Suarez G, Nathans D: Inhibition of aminoaryl-s RNA binding to ribosomes by tetracycline. Biochem Biophys Res Commun 18:743–750, 1965
Connamacher RM, Mandel HG: Binding of tetracycline to the 30s ribosomes and to polyuridylic acid. Biochem Biophys Res Commun 20:98–103, 1965
Hansen CH, Pearson LH, Schenker S, et al: Impaired secretion of triglycerides by the liver: a cause of tetracycline induced fatty liver. Proc Soc Exp Biol Med 128:143–146, 1968
Wolinsky E, Hines JD: Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. New Eng J Med 266:759–762, 1962
Shils ME: Renal disease and the metabolic effects of tetracycline. Ann Intern Med 58:389–408, 1963
Gross JM: Fanconi syndrome (adult type) developing secondary to the ingestion of outdated tetracycline. Ann Intern Med 58:523–528, 1963
Fulop M, Drapin A: Potassium depletion syndrome secondary to nephropathy apparently caused by outdated tetracycline. New Eng J Med 272:986–989, 1965
Grant NF, Whalley PJ, Baxter CR: Nonoliguric renal failure: report of a case. Obstet Gynec 34:675–679, 1969
Papper S, Vaamonde CA: Renal failure in cirrhosis: role of plasma volume. Editorial. Ann Intern Med 68:958–959, 1968
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robinson, M.J., Rywlin, A.M. Tetracycline-associated fatty liver in the male. Digest Dis Sci 15, 857–862 (1970). https://doi.org/10.1007/BF02236049
Issue Date:
DOI: https://doi.org/10.1007/BF02236049